1. Waziri B, Duarte R, Naicker S. Chronic Kidney Disease – Mineral and Bone Disorder (CKD-MBD): Current Perspectives. Int J Nephrol Renovasc Dis. 2019; 12: 263-76.
2. Delanaye P, Souberbielle J, Lafage-Proust M, Jean G, Cavalier E. Can We Use Circulating Biomarkers to Monitor Bone Turnover in CKD Haemodialysis Patients? Hypotheses and Facts. Nephrol Dial Transplant. 2014; 29: 997-1004.
3. Robinson KA, Rebholz CM, Wilson LM, Jirru E, Liu MC, Gayleard J, et al. Kidney Disease Improving Global Outcomes (KDIGO) 2017 Clinical Practice Guideline Update for the Diagnosis Evaluation, Prevention, and Treatment of Chronic Kidney Disease – Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017; 7: 1-59.
4. Kurpas A, Supeł K, Idzikowska K, Zielińska M. FGF23: A Review of Its Role in Mineral Metabolism and Renal and Cardiovascular Disease. Dis Markers. 2021 May 17;2021:8821292. doi: 10.1155/2021/8821292.
5. Zou D, Wu W, He Y, Ma S, Gao J. The role of klotho in chronic kidney disease. BMC Nephrol. 2018 Oct 22;19(1):285. doi: 10.1186/s12882-018-1094-z. PMID: 30348110;
6. Sprague SM, Bellorin-Font E, Jorgetti V, Carvalho AB, Malluche HH, Ferreira A, et al. Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients with CKD Treated by Dialysis. Am J Kidney Dis. 2016; 67 (4): 559-66.
7. Nizet A, Cavalier E, Stenvinkel P, Haarhaus M, Magnusson P. Bone alkaline phosphatase: An important biomarker in chronic kidney disease - mineral and bone disorder. Clin Chim Acta. 2020 Feb;501:198-206. doi: 10.1016/j.cca.2019.11.012. Epub 2019 Nov 14.
8. D'Arrigo G, Mallamaci F, Pizzini P, Leonardis D, Tripepi G, Zoccali C. CKD-MBD biomarkers and CKD progression: an analysis by the joint model. Nephrol Dial Transplant. 2023 Mar 31;38(4):932-938. doi: 10.1093/ndt/gfac212. PMID: 35790138.
9. Waziri B, Duarte R, Naicker S. Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Current Perspectives. Int J Nephrol Renovasc Dis. 2019 Dec 24;12:263-276. doi: 10.2147/IJNRD.S191156.
10. Chiang C. The use of bone turnover markers in chronic kidney disease-mineral and bone disorders. Nephrology (Carlton). 2017 Mar;22 Suppl 2:11-13. doi: 10.1111/nep.13014.
11. Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCAnn Lin, et al. Executive Summary of the 2017 KDIGO Chronic Kidney Disease – Mineral and Bone Disorder (CKD-MBD) Guideline Update: What’s Changed and Why it Matters. Kidney Int. 2017; 92 (1): 26-36.
12. Nugroho P. Management of Chronic Kidney Disease – Mineral and Bone Disorder (CKD-MBD). J Penyakit Dalam Indones. 2021; 8 (4): 218-27.
13. Rysz J, Franczyk B, Rokicki R, Gluba-Brzózka A. The Influence of Dietary Interventions on Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Nutrients. 2021 Jun 16;13(6):2065. doi: 10.3390/nu13062065.
14. Barreto FC, Barreto DV, Massy ZA, Drüeke TB. Strategies for Phosphate Control in Patients With CKD. Kidney Int Rep. 2019 Jun 20;4(8):1043-1056. doi: 10.1016/j.ekir.2019.06.002.
15. Hwang E, Choi BS, Oh K, Kwon YJ, Kim G. Management of Chronic Kidney Disease – Mineral and Bone Disorder: Korean Working Group Recommendations. Kidney Res Clin Pract. 2015; 34 (1): 4-12.
16. Cupisti A, Gallieni M, Rizzo MA, Caria S, Meola M, Bolasco P. Phosphate Control in Dialysis. Int J Nephrol Renovasc Dis. 2013; 6: 193-205
17. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, et al. Vitamin D Therapy and Cardiac Structure and Function in Patients with Chronic Kidney Disease. J Am Med Assoc. 2012; 307 (7): 674-84
18. Wang AY, Fang F, Chan J, Wen Y, Qing S, Chan IH, et al. Effect of Paricalcitol on Left Ventricular Mass and Function in CKD – the Opera Trial. J Am Soc Nephrol. 2014; 25 (1): 175-86.
19. Hou YC, Zheng CM, Chiu HW, Liu WC, Lu KC, Lu CL. Role of Calcimimetics in Treating Bone and Mineral Disorders Related to Chronic Kidney Disease. Pharmaceuticals (Basel). 2022 Jul 31;15(8):952. doi: 10.3390/ph15080952. PMID: 36015101; PMCID: PMC9415417.